BRIEF-Exelixis, Ipsen post results from advanced renal cell carcinoma study
June 06, 2016 at 07:45 AM EDT
* Exelixis and its partner Ipsen announce positive overall survival results from subgroup analyses of phase 3 trial of CABOMETYX(tm) (cabozantinib) tablets in advanced renal cell carcinoma at 2016 ASCO annual meeting
